Given the increasing risks of MACCEs in prostate cancer patients receiving GnRH therapy, the use of aspirin may further benefit cardiovascular outcomes beyond its effect on cancer survival (12, 26, 28). This evidence concerns the gene GNRH1 and prostate carcinoma.